Osteoporosis in patients with cystic fibrosis (Q77366707)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9759556%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

review article

1 reference

title

Osteoporosis in patients with cystic fibrosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9759556%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

1 reference

S M Ott

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9759556%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

M L Aitken

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9759556%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

publication date

1 September 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9759556%20AND%20SRC:MED&resulttype=core&format=json

Clinics in Chest Medicine

5 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9759556%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9759556%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9759556%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

page(s)

555-567

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9759556%20AND%20SRC:MED&resulttype=core&format=json

Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis

5 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970100-3

7 January 2021

Gains in bone mineral density with resolution of vitamin D intoxication

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970100-3

7 January 2021

Severe osteoporosis before and after lung transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970100-3

7 January 2021

Increased rate of fractures and severe kyphosis: sequelae of living into adulthood with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970100-3

7 January 2021

Osteopenia in adults with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970100-3

7 January 2021

Bone demineralization in cystic fibrosis: evidence of imbalance between bone formation and degradation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970100-3

7 January 2021

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970100-3

7 January 2021

Low serum bone gamma-carboxyglutamic acid protein concentrations in patients with cystic fibrosis: correlation with hormonal parameters and bone mineral density

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970100-3

7 January 2021

Treatment of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970100-3

7 January 2021

Nitric oxide and bone

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970100-3

7 January 2021

Osteoporosis in patients undergoing lung transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970100-3

7 January 2021

The changing epidemiology of cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970100-3

7 January 2021

Clinical pharmacology of alendronate sodium

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970100-3

7 January 2021

Osteoporosis in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970100-3

7 January 2021

Bone mineral density and body composition in adult patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970100-3

7 January 2021

Reduced serum 25-hydroxyvitamin D concentration and disordered mineral metabolism in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970100-3

7 January 2021

Effects of growth hormone treatment in children with cystic fibrosis: the National Cooperative Growth Study experience

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970100-3

7 January 2021

Vitamin D levels in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970100-3

7 January 2021

Bone density in children and adolescents with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970100-3

7 January 2021

Kyphosis and fractures in children and young adults with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970100-3

7 January 2021

Bone mineralization, hypothalamic amenorrhea, and sex steroid therapy in female adolescents and young adults

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970100-3

7 January 2021

Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970100-3

7 January 2021

25-Hydroxycholecalciferol levels in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970100-3

7 January 2021

Anabolic effect of biosynthetic growth hormone in cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970100-3

7 January 2021

Long-term effects of intravenous pamidronate in fibrous dysplasia of bone

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970100-3

7 January 2021

Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970100-3

7 January 2021

Relationship of bone turnover to bone density and fractures

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970100-3

7 January 2021

Prevention of corticosteroid-induced osteoporosis with salmon calcitonin in sarcoid patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970100-3

7 January 2021

Nasal administration of salmon calcitonin for prevention of glucocorticoid-induced osteoporosis in children with nephrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970100-3

7 January 2021

The prevalence of vertebral deformity in european men and women: the European Vertebral Osteoporosis Study

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970100-3

7 January 2021

Evaluation of vertebral volumetric vs. areal bone mineral density during growth.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970100-3

7 January 2021

Vitamin D metabolites in adolescents and young adults with cystic fibrosis: effects of sun and season

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970100-3

7 January 2021

Body composition analysis by dual-energy x-ray absorptiometry in adults with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970100-3

7 January 2021

Bone mineral content in cystic fibrosis patients: correlation with fat-free mass

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970100-3

7 January 2021

Inhibition of antigen-presenting cell function by alendronate in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970100-3

7 January 2021

Osteoporosis in lung transplantation candidates with end-stage pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970100-3

7 January 2021

Vitamin D and parathyroid hormone and bone mineralisation in adults with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970100-3

7 January 2021

Hypovitaminosis D in Medical Inpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970100-3

7 January 2021

10.1016/S0272-5231(05)70100-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9759556%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

1 reference